Cat. No.: HY-159579

CW-3308

Customer Review

Based on 1 Customer Validation

CW-3308 is an orally active BRD9 PROTAC degrader with an DC₅₀ of 92 nM. CW-3308 forms a ternary complex with BRD9 and cereblon to mediate BRD9 degradation. CW-3308 inhibits the viability of synovial sarcoma and rhabdoid tumor cells. CW-3308 reduces BRD9 protein levels in xenograft tumor tissues and suppresses tumor growth in xenograft models. CW-3308 can be used for the research of synovial sarcoma and rhabdoid tumors.
(Pink: BRD9 ligand (HY-159596); Blue: Cereblon ligand (HY-159597); Black: linker (HY-159598)).

For research use only. We do not sell to patients.

Purity: 99.43%
CAS No.: 3055592-99-6
Formula: C₄₅H₄₈N₆O₈
Molecular Weight:800.90

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

CW-3308 Chemical Structure

CAS No.: 3055592-99-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

CW-3308 is an orally active BRD9 PROTAC degrader with an DC₅₀ of 92 nM. CW-3308 forms a ternary complex with BRD9 and cereblon to mediate BRD9 degradation. CW-3308 inhibits the viability of synovial sarcoma and rhabdoid tumor cells. CW-3308 reduces BRD9 protein levels in xenograft tumor tissues and suppresses tumor growth in xenograft models. CW-3308 can be used for the research of synovial sarcoma and rhabdoid tumors^[1]. (Pink: BRD9 ligand (HY-159596); Blue: Cereblon ligand (HY-159597); Black: linker (HY-159598)).

IC₅₀ & Target^[1]

BRD9

5 nM (IC₅₀)

Cereblon

All PROTACs Isoforms :

All Epigenetic Reader Domain Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
G-401	IC₅₀	185 nM Compound: 27; CW-3308	Inhibition of cell viability in human G-401 cells incubated for 4 days by CellTiter-Glo luminescent cell viability assay Inhibition of cell viability in human G-401 cells incubated for 4 days by CellTiter-Glo luminescent cell viability assay	[PMID: 39132814]

In Vitro

CW-3308 (Compound 27) potently degrades BRD9 in genetically engineered HEK293 CRISPR knock-in cells after 6 h, with a DC₅₀ of 92 nM and a maximum degradation rate of 99%^[1].
CW-3308 (0.1-1000 nM; 3 h) potently and selectively degrades BRD9 in G401 and HS-SY-II cells^[1].
CW-3308 potently binds to purified BRD9 protein, with an IC₅₀ of 5.0 nM^[1].
CW-3308 (185 nM; 4 days) potently inhibits the viability of G401 and HS-SY-II cells, with IC₅₀ values of 185 nM and 2.7 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

G401 rhabdoid tumor cells
Concentration:

0, 0.1, 1, 10, 100, 1000 nM
Incubation Time:

3 h
Result:

Reduced BRD9 protein levels by 30% at 0.1 nM, 68% at 1 nM, 90% at 10 nM, 93% at 100 nM, and 86% at 1000 nM.
No significant degradation of BRD7 or BRD4 was observed at any tested concentration.

Western Blot Analysis^[1]

Cell Line:

HS-SY-II synovial sarcoma cells
Concentration:

0, 0.1, 1, 10, 100, 1000 nM
Incubation Time:

3 h
Result:

Reduced BRD9 protein levels by 16% at 1 nM, 70% at 10 nM, 98% at 100 nM, and 76% at 1000 nM.
No degradation was observed at 0.1 nM.

Western Blot Analysis^[1]

Cell Line:

G401 rhabdoid tumor cells
Concentration:

100 nM
Incubation Time:

0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 h
Result:

Reduced BRD9 protein levels by 77% at 0.5 h, 91% at 1 h, and ≥94% at all time points from 1.5 h to 4 h.

Cell Viability Assay^[1]

Cell Line:

G401 rhabdoid tumor cells
Concentration:

185 nM
Incubation Time:

4 days
Result:

Inhibited cell growth with an IC₅₀ of 185 nM and a maximum inhibition (Iₘₐₓ) of 90%.

Cell Viability Assay^[1]

Cell Line:

HS-SY-II synovial sarcoma cells
Concentration:

2.7 μM
Incubation Time:

4 days
Result:

Inhibited cell growth with an IC₅₀ of 2.7 μM and a maximum inhibition (Iₘₐₓ) of 94%.

Parmacokinetics

Species	Dose	Route	AUC_0-24	CL	V_ss	Bioavailability	C_max	T_1/2
Mice^[1]	3 mg/kg	i.v.	991 ng·h/mL	48 mL/min/kg	18.2 L/kg	91 %	/	/
Mice^[1]	5 mg/kg	p.o.	1499 ng·h/mL	/	/	91 %	172 ng/mL	3.7 h

In Vivo

CW-3308 (25-50 mg/kg; p.o.; single administration / 5 days per week for 25 consecutive days) reduces BRD9 protein levels in HS-SY-II xenograft tumor tissues of SCID mice and inhibits the growth of HS-SY-II xenograft tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

SCID mice^[1]
Dosage:

50 mg/kg/25, 50 mg/kg
Administration:

p.o.; single dose/daily 5 days/week; 25 days
Result:

Reduced BRD9 protein levels in tumor tissue by 92.5% relative to controls at 3 hours post-dose.
Reduced BRD9 protein levels in tumor tissue by 45% relative to controls at 24 hours post-dose.
Detected high drug concentrations in plasma and tumor tissue at 3 hours, with low concentrations present at 24 hours.
Achieved a maximum tumor growth inhibition (TGI) of 57% at 25 mg/kg.
Achieved a maximum tumor growth inhibition (TGI) of 60% at 50 mg/kg.
Observed no significant animal weight loss or other signs of toxicity during the study.

Chemical Information

CAS No. 3055592-99-6
Appearance Solid
Molecular Weight 800.90
Formula C₄₅H₄₈N₆O₈
Color White to light yellow
SMILES

O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=C4C(CN(CC(CC5)CCC65CCN(C(C7=C(OC)C=C(C(C8=CC=NC=C98)=CN(CC)C9=O)C=C7OC)=O)CC6)C4)=C3)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 4.17 mg/mL (5.21 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2486 mL

6.2430 mL

12.4860 mL

5 mM

0.2497 mL

1.2486 mL

2.4972 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wang C, et al. Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. J Med Chem. 2024;67(16):14125-14154. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2486 mL	6.2430 mL	12.4860 mL	31.2149 mL
DMSO	5 mM	0.2497 mL	1.2486 mL	2.4972 mL	6.2430 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CW-3308

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Blood Cancer Compound Library

PROTAC Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

All PROTACs Isoforms

All Epigenetic Reader Domain Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CW-3308

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Blood Cancer Compound Library

PROTAC Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

All PROTACs Isoforms

All Epigenetic Reader Domain Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CW-3308 Related Classifications

Cat. No.: HY-159579